Saving your money for next purchases
durvalumab,Imfinzi德瓦鲁单抗,度伐利尤单抗,度伐鲁单抗,英飞凡
Durvalumab (Durvalumab [4], trade name Imfinzi, Chinese trade name Imfinzi) is a fully humanized anti-PD-L1 monoclonal antibody used to treat cancer. The drug was developed by MedImmune, a wholly-owned subsidiary of AstraZeneca. [5] It is a human immunoglobulin G1κ (IgG1κ) monoclonal antibody that blocks PD-L1 and PD-1 (CD279)
Share:
Products
Our offers
Delivery – when you want and anywhere
A huge selection of best products
Health Classification
Let us work together to protect precious health
